解读类似葡萄糖-1受体激活剂对加速面部和皮肤衰老的影响
Aesthetic surgery journal
|June 14, 2024
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 可能通过影响脂肪组织和皮肤健康来加速面部衰老. 了解这些机制对于管理患者的意外化品副作用至关重要.
科学领域:
- 皮肤病学和内分泌学
- 衰老研究研究 衰老研究
- 代谢性疾病管理
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 广泛用于治疗2型糖尿病和肥胖症.
- 最近的观察表明,在使用GLP-1RAs的患者中,有意想不到的副作用,包括加速面部衰老和皮肤健康变化.
研究的目的:
- 审查关联GLP-1RAs的潜在机制,脂肪组织动态和过早的面部衰老.
- 探索GLP-1RA诱导的面部改变的临床影响和潜在的管理策略.
主要方法:
- 对研究GLP-1RAs对面部美学和皮肤健康的影响进行系统审查.
- 分析涉及脂肪组织,脂肪衍生干细胞 (ADSC) 和荷尔蒙/代谢因素的拟议机制.
主要成果:
- 使用GLP-1RA与多因素的面部衰老有关,包括面部白色脂肪组织的损失和ADSC功能的改变.
- 皮肤结构的变化,屏障功能,以及面部肌肉质量的潜在减少,都会导致老化的外观.
- 代谢,结构和激素途径都与GLP-1RA介导的脂肪组织调节有关.
结论:
- 需要更深入地了解GLP-1RA对面部脂肪组织的影响.
- 治疗策略应侧重于刺激ADSCs,利用自主脂肪转移和软组织填充剂等技术.
- 临床管理需要向积极处理GLP-1RA诱导的面部变化进行范式转变.
相关概念视频
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
170
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
170
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K


